Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
Article in Clinical Lung Cancer (March 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
Article in OncoImmunology (February 2024)
Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
Article in Frontiers in Immunology (May 2023)